摘要：
Objective To provide reference for optimizing China’s drug regulatory model and ensuring public medication
safety. Methods Literature review was used to investigate drug regulatory models in the United States, Japan, and
the European Union. Then, a comparative analysis was made. Results and Conclusion The comprehensive legal
frameworks, centralized regulatory authorities, specialized regulatory personnel, and multi-stakeholder regulatory
structures in these countries and regions offer valuable insights for improving and advancing China’s drug
supervision.
Hao Guiying, Huang Zhe. Comparative Study on Regulatory Models for Drug Safety
in the United States, Japan, and European Union[J]. 亚洲社会药学, 2026, 21(2): 115-123.
Hao Guiying, Huang Zhe. Comparative Study on Regulatory Models for Drug Safety
in the United States, Japan, and European Union[J]. Asian Journal of Social Pharmacy, 2026, 21(2): 115-123.
